Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
AstraZeneca
Mallinckrodt
Accenture
Chinese Patent Office
Colorcon
Queensland Health
Chubb
US Army

Generated: June 24, 2018

DrugPatentWatch Database Preview

Fingolimod - Generic Drug Details

« Back to Dashboard

Synonyms for fingolimod
1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-
1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-
1,3-Propanediol,2-amino-2-[2-(4-octylphenyl)ethyl]-
162359-55-9
2-(4-octylphenethyl)-2-aminopropane-1,3-diol
2-(4-octylphenylethyl)-2-aminopropane-1,3-diol
2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol
2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol
2-Amino-2-(4-octylphenethyl)propane-1,3-diol
2-amino-2-(4-octylphenyl)ethylpropane-1,3-diol
2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol
2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propandiol
2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol
2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
2-amino-2-hydroxymethyl-4-(4-(octyl)phenyl)butanol
3674AH
3B1-001911
3QN8BYN5QF
4CA-1387
ABP000245
AC-25899
AC1L332W
AK323625
AKOS015999594
AN-3555
ANW-53305
BDBM50158336
C19H33NO2
CHEBI:63115
CHEMBL314854
CS-2900
CTK8B6336
D07UHS
DB05286
DB08868
DTXSID40167363
Fingolimod (INN)
Fingolimod [INN]
FingoliMod Base
fingolimodum
FT-0660847
FTY720/Fingolimod, Gilenia
Gilenia
Gilenia (fingolimod)
Gilenya (TN)
GTPL2407
HY-11063
KKGQTZUTZRNORY-UHFFFAOYSA-N
KS-00000ZGE
LP009658
LS-187221
MolPort-003-847-513
NCGC00188399-01
NCGC00188399-03
SC-28385
SCHEMBL7445
ST2416326
STL445699
TC-142050
UNII-3QN8BYN5QF
ZINC1542002
Tentative approvals for FINGOLIMOD
Applicant Application No. Strength Dosage Form
➤ Try a Free Trial➤ Try a Free Trial0.5MGCAPSULE;ORAL
➤ Try a Free Trial➤ Try a Free Trial0.5MGCAPSULE;ORAL

US Patents and Regulatory Information for fingolimod

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis GILENYA fingolimod hydrochloride CAPSULE;ORAL 022527-001 Sep 21, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis GILENYA fingolimod hydrochloride CAPSULE;ORAL 022527-001 Sep 21, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis GILENYA fingolimod hydrochloride CAPSULE;ORAL 022527-001 Sep 21, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis GILENYA fingolimod hydrochloride CAPSULE;ORAL 022527-001 Sep 21, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Moodys
Citi
Healthtrust
UBS
Chubb
Dow
Medtronic
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.